ES2184340T3 - Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial. - Google Patents

Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial.

Info

Publication number
ES2184340T3
ES2184340T3 ES98959416T ES98959416T ES2184340T3 ES 2184340 T3 ES2184340 T3 ES 2184340T3 ES 98959416 T ES98959416 T ES 98959416T ES 98959416 T ES98959416 T ES 98959416T ES 2184340 T3 ES2184340 T3 ES 2184340T3
Authority
ES
Spain
Prior art keywords
inhibitors
enzyme
combinations
angiotensin conversion
matrix metaloproteinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98959416T
Other languages
English (en)
Inventor
Joseph Thomas Peterson Jr
Milton Lethan Pressler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2184340(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2184340T3 publication Critical patent/ES2184340T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composición farmacéutica que incluye una cantidad eficaz de un inhibidor de la enzima de conversión de la angiotensina y una cantidad eficaz de un inhibidor de la metaloproteinasa matricial.
ES98959416T 1997-12-23 1998-11-10 Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial. Expired - Lifetime ES2184340T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23

Publications (1)

Publication Number Publication Date
ES2184340T3 true ES2184340T3 (es) 2003-04-01

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98959416T Expired - Lifetime ES2184340T3 (es) 1997-12-23 1998-11-10 Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial.

Country Status (24)

Country Link
US (1) US6133304A (es)
EP (1) EP1047450B1 (es)
JP (1) JP2001526245A (es)
KR (1) KR20010033473A (es)
AR (1) AR015504A1 (es)
AT (1) ATE225187T1 (es)
AU (1) AU751701B2 (es)
BR (1) BR9814422A (es)
CA (1) CA2305436A1 (es)
CO (1) CO4970775A1 (es)
DE (1) DE69808518T2 (es)
DK (1) DK1047450T3 (es)
ES (1) ES2184340T3 (es)
HU (1) HUP0100427A3 (es)
IL (1) IL135428A0 (es)
IS (1) IS5446A (es)
NO (1) NO20003256D0 (es)
NZ (1) NZ503962A (es)
PE (1) PE20000065A1 (es)
PL (1) PL341335A1 (es)
PT (1) PT1047450E (es)
UY (1) UY25321A1 (es)
WO (1) WO1999032150A1 (es)
ZA (1) ZA9811794B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL350452A1 (en) * 1999-03-03 2002-12-16 Procter & Gamble Dihetero-substituted metalloprotease inhibitors
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
JPWO2003015762A1 (ja) * 2001-08-20 2004-12-02 小野薬品工業株式会社 心不全治療剤
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
EP1545287B1 (en) * 2002-10-04 2012-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Vasoregulating compounds and methods of their use
WO2004043383A2 (en) * 2002-11-07 2004-05-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7419801B2 (en) 2003-08-08 2008-09-02 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
AU2005268781A1 (en) * 2004-08-02 2006-02-09 Genmedica Therapeutics Sl Compounds for inhibiting copper-containing amine oxidases and uses thereof
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
JP2011525194A (ja) * 2008-06-20 2011-09-15 キネメッド， インコーポレイテッド 線維性疾患または病態を治療するための組成物
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2774389A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
SG2014011654A (en) 2011-08-30 2014-08-28 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2012302144B2 (en) 2011-08-30 2017-06-15 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9884085B2 (en) 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
CA2955379C (en) 2014-07-17 2022-12-13 Chdi Foundation, Inc. Methods and compositions for treating hiv-related disorders
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097208T3 (es) * 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.
CA2212713A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
IS5446A (is) 2000-04-14
BR9814422A (pt) 2000-10-10
PE20000065A1 (es) 2000-02-11
EP1047450B1 (en) 2002-10-02
WO1999032150A1 (en) 1999-07-01
HUP0100427A2 (hu) 2001-06-28
NO20003256L (no) 2000-06-22
NZ503962A (en) 2002-03-28
DK1047450T3 (da) 2003-01-27
US6133304A (en) 2000-10-17
PT1047450E (pt) 2003-02-28
NO20003256D0 (no) 2000-06-22
CO4970775A1 (es) 2000-11-07
CA2305436A1 (en) 1999-07-01
UY25321A1 (es) 2004-07-30
DE69808518T2 (de) 2003-06-26
EP1047450A1 (en) 2000-11-02
PL341335A1 (en) 2001-04-09
IL135428A0 (en) 2001-05-20
KR20010033473A (ko) 2001-04-25
DE69808518D1 (de) 2002-11-07
HUP0100427A3 (en) 2002-11-28
JP2001526245A (ja) 2001-12-18
AR015504A1 (es) 2001-05-02
ZA9811794B (en) 1999-06-29
ATE225187T1 (de) 2002-10-15
AU1522099A (en) 1999-07-12
AU751701B2 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
ES2184340T3 (es) Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial.
TR199501472A2 (tr) Matriks metaloproteaz inhibitörler.
NO990184D0 (no) Fosfintbaserte inhibitorer for mtriks-metalloproteaser
ES2161548T3 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa.
NO326882B1 (no) Inhibitorer for interleukin-1 konverterende enzym
BR9607412A (pt) Inibidor de trombina e composto
FI962315A (fi) Entsyymi-inhibiittorit
NO981938D0 (no) Proteaseinhibitorer
DE59608323D1 (de) Transdermal applizierbares arzneimittel mit ace-hemmern
ES2191830T3 (es) Inhibidores de trombina.
NO20004550D0 (no) Enzyminhibitorer
IT1298163B1 (it) Inibitori di solfammido-metalloproteasi
ATE239755T1 (de) Thrombin inhibitoren
DK0934259T3 (da) Beta-sulfonamidohydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer
DE69835215D1 (de) Inhibitoren von phosphoserin- und phosphothreoninspezifischen isomerasen
ID27192A (id) Sulfonamida trisiklik dan turunannya sebagai inhibitor metaloproteinase matriks
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
BR9709902A (pt) Inibidores de metalo-proteinase de matriz
EE200000644A (et) Interleukiin-1ß-t muundava ensüümi suktsiinamiidinhibiitorid
NO20000921D0 (no) Fibrinogenbasert vevklebemiddel
DK1047665T3 (da) Matrix metalloprotease inhibitorer
ES2186807T3 (es) Inhibidores de trombina.
TR199501429A2 (tr) Matriks metaloproteaz inhibitörlerinin yerine gecen 4-biarilpentanoik asitleri ve türevleri
TR199800847A3 (tr) Bir anjiyotensin dönüstürücü enzim inhibitörünün sabit doz bilesimi.